Andrew J. Ryan

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Response to: 'Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity'.

Response to: 'Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity'.

Journal: BJU international

Published: May 28, 2026

Granulomatous prostatitis masquerading as suspected prostate cancer in a young patient on immunotherapy for psoriasis.

Granulomatous prostatitis masquerading as suspected prostate cancer in a young patient on immunotherapy for psoriasis.

Journal: BMJ case reports

Published: April 24, 2026

Prostate-specific membrane antigen (PSMA)-PET-avid prostate cancers show stronger PSMA immunohistochemistry staining on biopsy cores.

Prostate-specific membrane antigen (PSMA)-PET-avid prostate cancers show stronger PSMA immunohistochemistry staining on biopsy cores.

Journal: BJU international

Published: March 18, 2026

Reply to Armando Stabile, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Jianliang Liu, Laurence Harewood, Dominic Bagguley, et al. Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer. Eur Urol Oncol 2025;8:1118-25.

Reply to Armando Stabile, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Jianliang Liu, Laurence Harewood, Dominic Bagguley, et al. Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer. Eur Urol Oncol 2025;8:1118-25.

Journal: European urology oncology

Published: February 02, 2026

Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?

Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?

Journal: BJU international

Published: January 08, 2026

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer.

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 26, 2025

The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.

The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.

Journal: The Journal of urology

Published: September 05, 2025

Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer.

Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer.

Journal: BJUI compass

Published: August 26, 2025

Functional outcomes and toxicity following focal low-dose-rate brachytherapy for low-intermediate risk prostate cancer.

Functional outcomes and toxicity following focal low-dose-rate brachytherapy for low-intermediate risk prostate cancer.

Journal: BJUI compass

Published: July 06, 2025

Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology.

Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology.

Journal: Molecular oncology

Published: March 20, 2025

p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer.

p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 25, 2024

Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer.

Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer.

Journal: European urology oncology

Published: November 17, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026